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Utrecht, the NetherlandsMicroRNA-103/107 regulate systemic glucose metabolism and
insulin sensitivity. For this reason, inhibitory strategies for these
microRNAs are currently being tested in clinical trials. Given
the high metabolic demands of the heart and the abundant car-
diac expression of miR-103/107, we questioned whether antago-
miR-mediated inhibition of miR-103/107 in C57BL/6J mice
impacts on cardiac function. Notably, fractional shortening
decreased after 6 weeks of antagomiR-103 and -107 treatment.
This was paralleled by a prolonged systolic radial and circumfer-
ential time to peak and by a decreased global strain rate. Histol-
ogy and electron microscopy showed reduced cardiomyocyte
area and decreased mitochondrial volume and mitochondrial
cristae density following antagomiR-103 and -107. In line,
antagomiR-103 and -107 treatment decreased mitochondrial
OXPHOS complexes’ protein levels compared to scrambled, as
assessed by mass spectrometry-based label-free quantitative
proteomics. MiR-103/107 inhibition in primary cardiomyocytes
did not affect glycolysis rates, but it decreased mitochondrial
reserve capacity, reduced mitochondrial membrane potential,
and altered mitochondrial network morphology, as assessed
by live-cell imaging. Our data indicate that antagomiR-103
and -107 decrease cardiac function, cardiomyocyte size, and
mitochondrial oxidative capacity in the absence of pathological
stimuli. These data raise concern about the possible cardiac
implications of the systemic use of antagomiR-103 and -107 in
the clinical setting, and careful cardiac phenotyping within
ongoing trials is highly recommended.Received 20 December 2017; accepted 18 December 2018;
https://doi.org/10.1016/j.omtn.2018.12.010.
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The heart is the most metabolically demanding organ within the body
due to its specialized function and limited capacity for energy sub-
strate storage. In the healthy heart, approximately 70% of the energy
demand is covered by the mitochondrial oxidation of fatty acids,
while the remaining 30% stems from carbohydrates, ketones, lactate,
and amino acids.1 The ATP generated in this way is mainly consumed424 Molecular Therapy: Nucleic Acids Vol. 14 March 2019 ª 2018 The
This is an open access article under the CC BY license (http://creatiby the myoﬁbrillar actin-myosin ATPase for the contraction/
relaxation of the cardiac muscle and by the Ca2+ ATPase for calcium
reuptake in the sarcoplasmatic reticulum.2 Without tightly controlled
energy supply and expenditure, cardiac function becomes severely
compromised,2 and derangements of cardiac substrate and energy
metabolism are considered to play a key role in the pathogenesis of
heart failure. Indeed, therapies to prevent the progression of heart
failure by improving the oxidative capacity of the heart are the
subjects of recent investigations.3,4
MicroRNAs (miRNAs) are a class of small non-coding RNA mole-
cules that act as post-transcriptional modulators of gene expression;
they are regulators of all major cell functions, including metabolism
and growth;5 and they have been implicated in the development of
cardiovascular disease.6 miRNAs have been shown to regulate cardiac
hypertrophy and ﬁbrosis.7,8 Other miRNAs have been implicated in
the regulation of metabolic pathways in general,9 or they have
emerged as potential contributors to the metabolic substrate transi-
tion in cardiac diseases more speciﬁcally.10–12 Recently, the paralog
miRNAs miR-103 and miR-107 were shown to regulate insulin resis-
tance.13 Indeed, antagomiR-mediated silencing of miR-103/107
had marked effects on hepatic and adipose tissue metabolism, thereby
signiﬁcantly improving systemic glucose tolerance and insulin sensi-
tivity in obesemice.13 ThesemiRNAs are, therefore, considered prom-
ising therapeutic targets for the treatment of diabetes; a clinical phase I
or IIA trial with antagomiR-103 and -107 to treat patients with type 2
diabetes and liver disease is currently ongoing (ClinicalTrials.gov:
NCT02826525).Authors.
vecommons.org/licenses/by/4.0/).
Figure 1. AntagomiR-103 and -107 Impair Cardiac
Function and Strain
(A) Timeline of the study. A, antagomiR-103 and -107. (B)
Analysis of fastedplasmaatweek3ofglucose, free fatty acids
(FFAs), and triglycerides. (C) Echocardiographic fractional
shortening (FS). (D) Schematic representation of the strain
analysis, depicting the short-axis view of the left ventricle
divided in the analyzed segmentsand indicating the radial and
circumferential axes of motion. (E) Echocardiographic radial
and circumferential strain and strain rate metrics. (F–H)
Quantification and representative pictures of (F) laminin
staining, indicating mean cardiomyocyte area (scale bar,
20 mm); (G) lectin staining, indicating capillary density (scale
bar, 20 mm); and (H) picrosirius red staining, indicating fibrosis
(scale bar, 1 mm). Scr, scrambled (40 mg/kg/day); Ant, an-
tagomiR (20 mg/kg/day antagomiR-103 and 20 mg/kg/day
antagomiR-107). Data are presented as mean ± SEM; n = 7
per group; *p < 0.05 versus scrambled; **p<0.01 versus
scrambled; $p<0.05andp=x versus same treatment at day 1.
www.moleculartherapy.orgMiR-103/107 have been shown to be expressed at medium-to-high
levels across many tissue types, including the heart.14 Importantly,
the speciﬁc effects of antagomiR-103 and -107 in the heart have not
been investigated yet. Considering the chief importance of balanced
metabolism for the heart and the impact of miR-103/107 on systemic
metabolism, it is essential to determine the role of miR-103/107 onMolecular Tcardiac function. Accordingly, in the present
study, we investigated if antagomiR-mediated in-
hibition of miR-103/107 in mice had an impact
on cardiac function and, if so, if this was related
to alterations in cardiac metabolism. We found
that antagomiR-103 and -107 treatment compro-
mised mitochondrial function and led to cardiac
structural and functional remodeling in the
absence of any (patho)physiological trigger.
RESULTS
AntagomiR-103 and -107 Treatment Impairs
Cardiac Function in Healthy Adult Mice
To study the effect of the inhibition of
miR-103/107 on cardiac function and meta-
bolism of unstressed hearts, antagomiR-103 and
-107 was injected into adult mice (Figure 1A).
After 6 weeks, the expression of both miRNAs
was reduced by 70% in the heart and by >95%
in the liver following antagomiR-103 and -107
treatment, compared to scrambled oligo-treated
controls (Figure S1), demonstrating the effective-
ness of the antagomiR-103 and -107 treatment.
First, we explored the effect of the antagomiR-
103 and -107 on systemic metabolism, and we
monitored circulating free fatty acid, triglyceride,
and glucose levels over the course of 6 weeks. In
line with a previous study,13 fasting glucose levelstended to decrease in the antagomiR-103 and -107 group compared to
control after 3 weeks (Figure 1B). At the same time, the levels of free
fatty acids and triglycerides were unchanged between groups (Fig-
ure 1B). Hematological analysis at sacriﬁce showed a signiﬁcant
decrease in total white blood cell counts and lymphocyte counts in
the antagomiR-103 and -107 group as compared to scrambledherapy: Nucleic Acids Vol. 14 March 2019 425




Mean ±SD Mean ±SD
Heart weight/tibia length (mg/mm) 6.00 0.157 6.05 0.228
Liver weight/tibia length (mg/mm) 65.13 1.533 64.00 1.460
Kidney weight/tibia length (mg/mm) 8.90 0.188 8.87 0.351
Lung weight/tibia length (mg/mm) 8.88 0.226 9.46 0.258
Spleen weight/tibia length (mg/mm) 5.17 0.195 5.77 0.202
Body weight (week 0) 22.00 0.415 22.42 0.513
Body weight (week 6) 26.00 0.388 25.98 0.348
n = 7 per group; statistical differences were not observed.
Molecular Therapy: Nucleic Acidscontrols (Table S1). Differences in neutrophil and monocyte counts
were not observed (Table S1). Morphometric parameters did not
show differences between experimental groups (Table 1). These
data indicate that antagomiR-103 and -107 only had mild effects on
systemic metabolism in healthy, non-obese mice.
To monitor cardiac effects of the inhibition of the two miRNAs, left
ventricle (LV) systolic function was evaluated by echocardiographic
analysis at 1 day, 4 weeks, and 6 weeks after the start of antago-
miR-103 and -107 treatment. At day 1 and week 4, cardiac fractional
shortening (FS) was comparable between groups (Figure 1C).
Remarkably, at week 6, the antagomiR-103 and -107 group presented
a modest but signiﬁcant reduction in FS compared to scrambled
control. To gain more detailed information on the dynamics of
myocardial contraction in the LV, we performed speckle-tracking
strain analysis, and we assessed global LV circumferential and radial
strains as well as time to peak (TTP) systolic strain and peak systolic
strain rates in both dimensions (Figures 1D and 1E). In line with the
decreased FS at 6 weeks, antagomiR-103 and -107 treatment led to a
prolonged TTP in both radial and circumferential dimensions after 4
and 6 weeks compared to day 1 and for the circumferential dimension
also compared to scrambled control (Figure 1E). However, the scram-
bled control group did not show a difference in TTP over the time of
the study. Consistent with the decreased LV systolic function
observed in terms of FS, ejection fraction (EF), and TTP (Figure 1E;
Table 2), 6 weeks of antagomiR-103 and -107 treatment led to
decreased global strain in both radial and circumferential planes
compared to day 1 (Figure 1E). AntagomiR-103 and -107 treatment
also led to reduced peak systolic radial strain rate after 6 weeks and
peak systolic circumferential strain rate after 4 and 6 weeks (Fig-
ure 1E). Remarkably, the inhibition of miR-103/107 led to decreased
cardiomyocyte size without modifying the capillary density and car-
diac ﬁbrosis, as assessed by histological analysis (Figures 1F–1H).
Taken together, chronic treatment with antagomiR-103 and -107 led
to a signiﬁcant decrease of LV systolic function paralleled by a pro-
longed TTP LV contraction and a decreased systolic strain rate, in
the absence of any (patho)physiological trigger.426 Molecular Therapy: Nucleic Acids Vol. 14 March 2019AntagomiR-103 and -107 Do Not Affect the Inotropic State
The echocardiographic strain analysis, which showed prolonged TTP
and decreased systolic strain rate upon miR-103/107 inhibition, may
point toward a negative inotropic effect of antagomiR-103 and -107.
Negative inotropic agents can decrease myocardial force and
contractility by slowing cardiomyocyte Ca2+ ﬂux or by reducing
Ca2+ sensitivity of sarcomeric proteins via phosphorylation or
dephosphorylation. However, the phosphorylation status of phos-
pholamban (PLB) and cardiac troponin I (p-TnI), key regulators of
sarcoplasmic reticulum Ca2+ sequestration and myoﬁlament Ca2+
sensitivity that become phosphorylated upon inotropic stimulation,
was not signiﬁcantly changed upon antagomiR-103 and -107
treatment (Figures 2A and 2B). In addition, phosphorylation of
Ca2+/calmodulin-dependent protein kinase II (p-CaMKII), essential
for Ca2+ homeostasis and for the regulation of the contraction-
relaxation cycle, did not differ between antagomiR-103 and -107-
treated and control mice (Figures 2A and 2B). These results indicate
that the observed effect of antagomiR-103/107 treatment on myocar-
dial strain is not likely to be due to alterations in inotropic state.
AntagomiR-103 and -107 Modifies the Cardiac Proteome
To gain insight into underlying processes that could drive cardiac
dysfunction and remodeling upon the inhibition of miR-103/107,
we performed a miR-103/107 target analysis. According to the online
database TargetScan,15 miR-103/107 have 838 predicted targets,
which can be grouped according to their biological function using
the PANTHER gene annotation database16 (Figure S2). Interestingly,
29% of anticipated miR-103/107 targets are associated with meta-
bolic processes, including carbohydrate as well as lipid metabolism.
To further probe the mechanism underlying the antagomiR-103 and
-107-induced alterations in cardiac function, we performed mass
spectrometry (MS)-based label-free quantitative proteomics on LV
tissue from scrambled and antagomiR-103 and -107-treated mice.
Unsupervised clustering analysis of the MS data clearly separated
the scrambled control and the antagomiR-103 and -107 group (Fig-
ure 3A), underscoring the effect of antagomiR-103 and -107 on
cardiac phenotype. Anticipated targets of miR-103/107, including
mitochondrial proteins, were differentially expressed upon antago-
miR-103 and -107 treatment (Table S2). The generated data were
integrated into the pathway analysis application PathVisio for the
visualization of differentially regulated pathways related to sarcomere
function and metabolism. Multiple proteins involved in striated mus-
cle contraction as well as the mitochondrial electron transport chain
(ETC) were found to be differentially expressed following antagomiR-
103 and -107 treatment (Figures 3B and 3C; Table S2). Indeed, anta-
gomiR-103 and -107 affected protein levels within the ETC complexes
I, III, IV, and V as compared to scrambled control (Figure 3C).
AntagomiR-103 and -107 Decrease Cardiomyocyte
Mitochondrial Volume Density
In view of the reported role of miR-103/107 in regulating meta-
bolism,17 the prominence of predicted targets related to metabolism
(Figure S2), and our MS data on the ETC, we decided to focus on
Table 2. Echocardiographic Parameters
Parameter








Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Average wall thickness (mm) 0.77 0.09 0.86* 0.06 0.83 0.06 0.77* 0.10 0.83 0.13 0.82 0.07
Heart rate (bpm) 546.71 39.00 583.00 42.00 548.29 30.00 570.00 32.00 532.00 36.00 576.00* 29.00
LV volume diastolic (mL) 28.34 3.98 25.40 7.12 34.60 7.62 40.69 7.33 35.58 8.59 39.13 9.50
LV volume systolic (mL) 63.78 7.68 63.52 14.48 80.19 10.25 88.08 13.45 80.68 12.82 80.67 18.78
Stroke volume (%) 35.44 4.66 38.12 7.78 45.59 4.25 47.39 7.50 45.10 5.98 41.54 10.52
Ejection fraction (%) 55.60 3.35 60.31 3.15 57.22 4.92 53.84 3.89 56.25 5.33 51.43* 4.62
Fractional shortening (%) 28.50 2.23 31.66 2.13 29.85 3.23 27.67 2.47 29.23 3.49 26.06* 2.91
Circ. TTP/cycle time () 0.47 0.06 0.44 0.07 0.45 0.04 0.52*$ 0.05 0.45 0.03 0.52*$ 0.05
Radial TTP/cycle time () 0.48 0.06 0.43 0.07 0.46 0.04 0.53 0.05 0.45 0.03 0.56$ 0.05
Global circ. strain (%) 21.53 5.05 22.22 3.74 21.16 4.75 19.38 2.35 20.52 3.24 17.62* 2.04
Global radial strain (%) 24.54 10.08 26.91 3.95 25.68 4.19 26.67 6.24 22.84 8.22 21.76* 3.69
Circ. strain rate diastolic (1/s) 10.18 1.54 9.50 1.34 10.38 1.96 10.79 1.35 8.81 1.49 9.53 0.64
Circ. strain rate systolic (1/s) 9.04 2.19 9.87 2.69 8.50 1.66 7.24* 0.77 7.73 1.39 7.14* 0.83
Radial strain rate diastolic (1/s) 9.27 2.35 9.13 2.35 9.95 1.83 12.03*$ 1.35 7.74 2.10 10.11 1.88
Radial strain rate systolic (1/s) 7.98 2.45 8.89 1.50 7.92 0.67 8.23 1.99 7.82 0.99 6.86* 0.71
n = 7 per group; *p < 0.05 versus scrambled, $p < 0.05 versus same treatment at day 1. circ., circumferential.
www.moleculartherapy.orgthe effects of miR-103/107 inhibition on cardiac energy metabolism,
as a possible explanation for the decline in cardiac function. As a ﬁrst
general characterization of cardiac energy status, we investigated the
number and size distribution of the mitochondria within cardiomyo-
cytes by means of transmission electron microscopy (Figure 4A).
Notably, mitochondrial volume density was signiﬁcantly lower in
the antagomiR-103 and -107-treated group as compared to scrambled
control. The number of mitochondria was not changed signiﬁcantly,
but there was a general trend toward smaller-sized mitochondria in
the antagomiR-103 and -107-treated group compared to scrambled
control (p = 0.1; Figure 4A). In the high-resolution images, mitochon-
drial morphology was visibly altered in the antagomiR-103 and -107-
treated group, as revealed by the mitochondrial cristae appearance
(Figure 4B). Together, the negative effects of antagomiR-103 and
-107 on mitochondrial volume density and on ETC protein expres-
sion may point to a reduction in cardiac mitochondrial capacity
following antagomiR-103 and -107 treatment.
miR-103/107 Inhibition in Cardiomyocytes Reduces
Mitochondrial Respiration
Given the effects of in vivo antagomiR-103 and -107 treatment on
cardiac mitochondrial indices, we next investigated the effects of
miR-103/107 inhibition on substrate uptake and energy metabolism
in cardiomyocytes in vitro. First, we measured the degree of insulin-
stimulated glucose and palmitate uptake in HL-1 cardiomyocytes. In
line with our previous results,18 insulin stimulation induced the uptake
of glucose and tended to induce palmitate uptake in HL-1 cardiomyo-
cytes (Figure 5A). Importantly, miR-103/107 inhibition did notsigniﬁcantly change the level of glucose or palmitate uptake as
compared to control, neither under basal nor under insulin-
stimulated conditions (Figure 5A). These data indicate that the
inhibition of miR-103/107 in cardiomyocytes does not alter the
substrate uptake rate in cardiomyocytes.
To assess the effects of miR-103/107 on energy expenditure, substrate
utilization, and mitochondrial respiration, neonatal rat cardiac myo-
cytes (nRCMs) were transfected with inhibitors for miR-103/107 or
negative control, and metabolic assessment was conducted by meta-
bolic ﬂux analysis (Seahorse). miR-103/107 inhibition did not affect
the extracellular acidiﬁcation rate (ECAR), an indirect measure for
glycolysis, but it decreased glycolytic capacity as compared to control
(Figures 5B and 5C). miR-103/107 inhibition signiﬁcantly decreased
the oxygen consumption rate (OCR), a measurement of mitochondrial
respiration, at baseline and even more so after maximal stimulation by
Carbonyl cyanide p-triﬂuoromethoxyphenylhydrazone (FCCP) (Fig-
ures 5D and 5E), as reﬂected by lower basal and maximal respiration
(Figure 5E). These data suggest that the inhibition of miR-103/107
decreases mitochondrial respiration in cardiomyocytes.
Additionally, to investigate the effects of miR-103/107 inhibition on
mitochondrial function and morphology, nRCMs were transfected
with inhibitors for miR-103/107 or negative control and stained with
Tetramethylrhodamine methyl ester (TMRM) to monitor mitochon-
drial membrane potential and mitochondrial network structure. We
quantiﬁed TMRM signal intensity, and we assessed mitochondrial
morphology three-dimensionally in live nRCMs with spinning-discMolecular Therapy: Nucleic Acids Vol. 14 March 2019 427
Figure 2. AntagomiR-103 and -107 Do Not Affect Phosphorylation of Proteins Involved in Cardiac Ca2+ Homeostasis
(A) Representative western blot of the lysates of hearts treatedwith antagomiR-103 and -107 or scrambled. (B) Quantification of western blot. Scr, scrambled; ant, antagomiR.
Data are presented as mean ± SEM; n = 3 per group.
Molecular Therapy: Nucleic Acidsmicroscopy. miR-103/107 inhibition did not signiﬁcantly affect
cell volume, mitochondrial volume, or number of mitochondria
(Figures 6A and 6B). Reduced totalmitochondria intensity as well as in-
tensity per mitochondrion were indicative of changes in mitochondrial
membrane potential due to the inhibition of miR-103/107 (Figure 6B).
In addition, mitochondrial networks were more fragmented after
miR-103/107 inhibition, as reﬂected by signiﬁcantly smaller largest
mitochondrial fractions. Finally, individual mitochondria were smaller
in nRCM following the inhibition of miR-103/107 (Figure 6B).
These results are in line with our in vivo data on decreased sarcomeric
mitochondrial volume density as well as changes in mitochondrial
morphology, ETC protein levels, and the mild reduction in cardiac
function.
Taken together, our data show that chronic inhibition of miR-103/107
in healthy mice compromises mitochondrial function and leads to
cardiac structural and functional remodeling.
DISCUSSION
The protective function of antagomiR-103 and -107 on systemic
glucose metabolism and insulin sensitivity has been recently estab-
lished for metabolic disease.13 In this study, we applied antagomiR-
103 and -107 and disclosed their effect on cardiac function and
cardiomyocyte metabolism. We showed that systemic delivery of an-
tagomiR-103 and -107 in healthy mice reduced cardiac LV function,
as indicated by decreased FS and strain rate in the absence of patho-
logical stimuli. In addition, antagomiR-103 and -107-treated mice
presented with a diminished cardiac mitochondrial volume density
as well as decreased protein levels of the striated muscle contraction
and the ETC complexes. The investigation of cardiomyocyte meta-
bolism upon miR-103/107 inhibition showed a reduced mitochon-
drial respiratory capacity. Our results suggest that miR-103/107
inhibition affects cardiac systolic function via the modulation of428 Molecular Therapy: Nucleic Acids Vol. 14 March 2019mitochondrial respiration, without affecting the overall ATP avail-
ability for the cardiomyocytes. Which one(s) of the predicted targets
of miR-103/107 is responsible for mediating the observed effect on
cardiac function remains to be established.
miR-103 and miR-107 are conserved in all known vertebrate species
and are paralogs that differ only at a single nucleotide, and, hence,
they are thought to have overlapping targets.17 miR-103 and miR-
107 are located within introns of genes coding for pantothenate
kinases (PANKs). PANKs are enzymes that regulate cellular coenzyme
A levels, affecting multiple metabolic reactions, including the synthesis
of fatty acids, amino acids, cholesterol, pyruvate, glucose, and tricar-
boxylic acid (TCA) cycle intermediates.17 Based on the fact that
miRNA expression is often correlated with their host gene expression,
it has been proposed that miR-103/107 also play a signiﬁcant role in
PANK-associated metabolic reactions.17 Moreover, bioinformatics
target prediction indicated that miR-103/107 target exceptionally
more metabolic enzymes than usually seen from miRNAs. These pre-
dictions include fatty acid synthase, carnitine palmitoyl transferase I,
and pyruvate dehydrogenase.17 Accordingly, using TargetScan15 and
PANTHER databases,16 we found that 29% of anticipated miR-
103/107 targets are associated with metabolic processes, including car-
bohydrate as well as lipid metabolism. In the current study, we were
not able to detect signiﬁcant changes in cardiac metabolic gene expres-
sion at the mRNA level following antagomiR-103 and -107 treatment.
However, in line with a previous study,13 these regulatory effects could
be detected in liver tissue (data not shown), the main tissue targeted by
antagomiR nucleotides. Since miR-103/107 were incompletely in-
hibited in the heart (about 70%), it is conceivable that some residual
regulation by miR-103/107 still took place. However, this remains to
be further investigated.
Increased expression of miR-103/107 in liver has been associated with
insulin resistance in patients with alcoholic liver disease, nonalcoholic
(legend on next page)
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Molecular Therapy: Nucleic Acidsfatty liver disease, and nonalcoholic steatohepatitis, conditions often
associated with diabetes.19 Moreover, previous studies of miRNA
microarray analysis, aimed at selecting the most deregulated
miRNAs in obesity and insulin resistance, found miR-103/107 to
be among the most upregulated in the livers of two types of obese
mice, ob/ob and diet-induced obese mice,13 and the expression of these
miRNAswas also reportedly increased in diabeticGoto-Kakizaki rats.20
These data indicated an association of miR-103/107 with insulin resis-
tance,which led to the idea of using antagomiRs againstmiR-103/107 as
an anti-diabetic drug.13 Liver-speciﬁc overexpression of miR-103/107
in mice induced hyperglycemia and hyperinsulinemia, and also it
impaired glucose tolerance,13 suggesting that increased miR-103/107
levels during liver disease associated with diabetes may contribute to
disease progression. Conversely, antagomiR-103 and -107 treatment
in obese mice improved glucose tolerance and insulin sensitivity in
liver and adipose tissue, and it rescued b-oxidation pathway genes
like Cpt1.13 Currently, a clinical phase I or IIa trial is ongoing, which
applies antagomiR-103 and -107 in patients with steatohepatitis and
type 2 diabetes. In line, in our study antagomiR-103 and -107 treatment
led to a trend to decreased plasma glucose in healthy animals.
To study the myocardial deformation pattern, we performed speckle-
tracking echocardiography analysis. Speckle-tracking echocardiogra-
phy is widely used in the clinical setting for the assessment of
global and regional systolic function in patients with heart failure
and apparently normal EF.21 While EF and FS are parameters that
describe themyocardial pump function, strain and strain rate quantify
the contractility pattern of the myocardium.22,23 In the present study,
while the systolic strain rate decreased at weeks 4 and 6 in the
antagomiR-103 and -107-treated group, the diastolic strain rate was
increased at week 4 in the radial plane. This suggests a possible partial
compensation for the prolonged systolic phase, as indicated by TTP.
Thesemeasurements ﬁt with a normal physiological range of LV func-
tion in which the heart is able to compensate for a prolonged systolic
phase with a higher strain rate of relaxation. These ﬁndings are
particularly important since antagomiR-103 and -107 are currently
being investigated for clinical application in a phase I or IIa clinical
trial. Our results may be indicative of an effect on cardiac function
within the patient population of the ongoing clinical trial, which
had originally been enrolled for the presence of liver metabolic dis-
ease. In this context, it is noteworthy that the current ﬁndings are
derived from studies with healthy, unstressed animals. It is well
feasible that the observed depression of cardiac function may be
even more pronounced in the challenged heart.
Among the physiological modiﬁers of cardiac contractile force and
speed of contraction, we investigated the effect of antagomiR-103
and -107 on the cardiac inotropic state, by measuring the phosphor-Figure 3. AntagomiR-103 and -107 Modify the Cardiac Proteome
(A) Unsupervised mass spectrometry-protein abundancies clustering resulting from the
Discoverer 2.2 (Thermo Scientific). Green, scrambled (n = 3); red, antagomiR-103 an
and (C) ETC protein levels quantified by mass spectrometry of heart lysates. Green colo
red coloring indicates an increased expression, and yellow coloring indicates a signific
430 Molecular Therapy: Nucleic Acids Vol. 14 March 2019ylation status of proteins involved in Ca2+ homeostasis. Phospholam-
ban (PLB) modulates sarcoplasmic reticiulum Ca2+ uptake by
inhibiting sarco/endoplasmic reticulum Ca2+-ATPase (SERCA),24
and it becomes phosphorylated upon cyclic AMP (cAMP)-protein
kinase A (PKA) stimulation. We did not detect changes in PLB phos-
phorylation or total PLB (t-PLB) in antagomiR-103 and -107-treated
mice as compared to controls. Moreover, CaMKII signaling is central
in cardiac contractility and calcium handling.25 Activated and phos-
phorylated CaMKII, associated with the sarcoplasmic reticulum,
regulates both calcium uptake and release functions with each cycle
of contraction and relaxation.25 We analyzed cardiac protein levels
of total TnI (t-TnI) and p-TnI, and we did not ﬁnd a difference be-
tween antagomiR-103 and -107 treatment and control. Although
there was no deﬁnitive proof, the absence of changes in phosphoryla-
tion of these proteins suggests that the observed decline in cardiac
function is not secondary to alterations in inotropic state.
Interestingly, antagomiR-103 and -107 treatment led to changes in
contractile protein expression, as assessed byMS, and it was associated
with a reduction in cardiomyocyte size. Together, this points to an
active cardiac remodeling process induced by the antagomiR-103
and -107 treatment. Despite smaller cardiomyocytes following antago-
miR-103 and -107 treatment, total heart weight and cardiac wall di-
mensions were not affected, which might imply an increased volume
of the interstitial space and the presence of edema. It remains to be
established if these observations are a reﬂection of atrophic or
apoptotic processes26 and, importantly, if this contributes to the
decline in cardiac function.
The impairment of bioenergetics is considered key in the development
of heart failure (HF).27 TheATP that themyocardium has to synthesize
and transfer to sustain the excitation-contraction couplingmust contin-
uously support an optimalmyocardial performance in both systolic and
diastolic phases.27 ATP availability is crucial for Ca2+ homeostasis dur-
ing the excitation-contraction cycle,28 andmost of theATPderives from
mitochondrial oxidative phosphorylation. In light of the current knowl-
edge and of our in vivo data on the decreased cardiac levels of multiple
proteins of the mitochondrial ETC, one possible explanation for the
observed contractile dysfunction in this study is that, in antagomiR-
103 and -107-treated hearts, mitochondrial function, and thus ATP
synthesis, gets compromised. The effects of miR-103/107 inhibition
on mitochondrial membrane potential, an indicator of mitochondrial
health, as shown by the live-cell imaging of the uptake of TMRM and
the increased mitochondrial network fragmentation, are in support of
this reasoning. Since calcium is an important signaling molecule
involved in the ATP-consuming cardiac muscle contraction and
relaxation,22 future investigations should consider contractility readouts
in cardiomyocytes of mice treated with antagomiR-103 and -107.multivariate analysis (principal-component analysis [PCA]) by the software Proteome
d -107 (n = 3). (B and C) PathVisio visualization of (B) striated muscle contraction
ring indicates less expression of protein in antagomiR-103 and -107-treated mice,
ant q-value (q < 0.01).
Figure 4. AntagomiR-103 and -107 Decrease Cardiac Mitochondrial Volume Density
(A) Mitochondrial volume density and size range quantification. TEM images show cardiac tissue of antagomiR-103 and -107- or scrambled-treated hearts at 1,900
magnification (n = 5 per group). Data are presented as mean ± SEM; *p < 0.05 versus scrambled. (B) TEM images visualizing mitochondrial morphology of antagomiR-103
and -107- or scrambled-treated hearts at 6,800 magnification. Scr, scrambled; Ant, antagomiR.
www.moleculartherapy.orgA validated target of miR-103/107 is caveolin-1 (Cav-1),13 the
principal structural protein of caveolae, which are membrane do-
mains that have been implicated in signal transduction.29,30 Traj-
kovski and colleagues13 have shown that Cav-1 upregulation isparalleled by a concomitant stabilization of the insulin receptor.
Moreover, Meshulam and colleagues31 have shown that the expres-
sion of Cav-1 facilitates the uptake of fatty acids. Indeed, caveolae
have been suggested to participate in lipid transport, and they mayMolecular Therapy: Nucleic Acids Vol. 14 March 2019 431
Figure 5. miR-103/107 Inhibition in Cardiomyocytes Decreases Mitochondrial Respiration
(A) Bar graphs of insulin-stimulated glucose and palmitate uptake of HL-1 cells transfected with scrambled control or inhibitors for miR-103/107. (B) XF trace of the
extracellular acidification rate (ECAR) of nRCM transfected with scrambled control or inhibitors for miR-103/107. (C) Glycolysis and glycolytic capacity quantification from
(B). (D) XF trace of the oxygen consumption rate (OCR) of nRCM transfected with scrambled control or inhibitors for miR-103/107. (E) Quantification of mitochondrial basal
and maximal respiration from (D). 2-DG, 2-deoxyglucose; FCCP, Carbonyl cyanide p-trifluoromethoxyphenylhydrazone; scr, scrambled; ant, inhibitors. Data are presented
as mean ± SEM of at least 4 replicates; *p < 0.05 versus scr.
Molecular Therapy: Nucleic Acidsserve as organizing centers for a variety of receptors and signal-
transducing molecules.32 In light of this function of Cav-1, we
have studied the substrate uptake of HL-1 cardiomyocytes upon
the inhibition of miR-103/107, and we found that the substrate
uptake was not affected upon the inhibition of miR-103/107 at
baseline.Conclusions
The current ﬁndings highlight the role of miR-103/107 in cardiac
function. We show that systemic inhibition of miR-103/107 by means
of antagomiRs decreases cardiac systolic function, as reﬂected by the
reduced FS and systolic strain rate, in the absence of pathological432 Molecular Therapy: Nucleic Acids Vol. 14 March 2019stimuli. In addition, antagomiR-103 and -107 led to decreased cardiac
mitochondrial volume density, altered mitochondrial morphology,
and reducedmitochondrial OXPHOS protein content andmembrane
potential. The present ﬁndings raise concern on the possible cardiac
implications for the use of antagomiR-103 and -107 as an anti-dia-
betic drug, and careful cardiac phenotyping within ongoing clinical
trials is highly recommended.MATERIALS AND METHODS
Animals
All animal experiments were approved by the Institutional Animal
Care and User Committee of Maastricht and Leuven Universities,
Figure 6. miR-103/107 Inhibition in Cardiomyocytes Affects Mitochondrial Morphology
(A) Maximum-intensity projections of nRCMs stained with calcein (green), Hoechst (blue), and TMRM (red) to visualize cytosol, nuclei, and mitochondria, respectively. Scale
bar, 10 mm. (B) Mitochondrial network analyses including cell and mitochondria volume, mitochondrial intensities (reflecting mitochondrial membrane potential) as measured
by TMRM fluorescence, and quantification of mitochondrial number and size. Scr, scrambled; ant, inhibitors. Data are presented as mean ± SEM of 40 individually analyzed
cells per condition; *p < 0.05 versus scr.
www.moleculartherapy.organd they were performed adhering to the Dutch and Belgian law.
C57BL/6J male mice were included in the experiment at the starting
age of 7 weeks (Figure 1A). C57BL/6J mice (7/group) were injected
with either scrambled RNA (40 mg/kg/day) or antagomiR-103
and -107 (40 mg/kg/day) at experimental days 0, 1, 8, and 29. Anta-
gomiRs were RNA oligos complementary to miR-103 and miR-107,
20-0-methyl modiﬁed, harboring a 30-cholesterol type 1 modiﬁcation
and 5–7 phosphorothioate internucleotide linkages. Sequences were
as follows: antagomir miR-107-3p, 50-U*G*AUAGCCCUGUACAA
UGCU*G*C*U*Chol*T-30; antagomir miR-103a1-3p, 50-U*C*AUA
GCCCUGUACAAUGCU*G*C*U*Chol*T-30; and antagomir scram-
bled, 50-C*A*GCUGAAGUAAAUACCGAC*C*A*G*Chol*T-30 (Fi-
delity Systems, Gaithersburg, MD).Systolic blood pressure was monitored at weeks 3 and 6 by
means of tail cuff (CODA, Kent Scientiﬁc, Torrington, CT). Glyce-
mia was assessed at day 21 in plasma after a 6-h fast. Cardiac
function was assessed by echocardiography at days 0, 28, and 41
under isoﬂurane anesthesia (mean 1% in oxygen) with the
Vevo model 2100 from FUJIFILM (VisualSonics, Amsterdam,
the Netherlands), with probe MS400 18–38 MHz. For the
duration of the study, mice were housed in groups of four to
ﬁve in ventilated cages in a temperature-controlled room with a
12-h light-dark cycle and ad libitum access to food and water.
At day 42, animals were euthanized; blood and organs were pro-
cessed for electron microscopy and histological and molecular
analyses.Molecular Therapy: Nucleic Acids Vol. 14 March 2019 433
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Echocardiographic M-mode and B-mode images were acquired in
mid-ventricular views at the height of the papillary muscles. Heart
rate was obtained from the short axis B-mode. LV dimensions were
measured in systole and diastole. Cardiac strain measurements were
obtained from parasternal short-axis B-mode images using the Vevo-
Strain software (Visualsonics). Images with clear visibility of endocar-
dial and epicardial borders throughout the cardiac cycle and with
minimal image artifacts were selected for strain analysis. Three to
four consecutive cardiac cycles were selected, then endocardial and
epicardial borders were traced semi-automatically and manually
adjusted for tracking during the cardiac cycle. Using speckle-
tracking-based strain analysis, circumferential and radial strain and
strain rate time curves were quantiﬁed in six adjacent segments.
Frame rate was 333/s for all 2D B-mode acquisitions. Several LV sys-
tolic function metrics were obtained from the circumferential and
radial strain and strain rate time curves. TTP shortening was deﬁned
as the time from onset QRS to peak systolic shortening, averaged
over all segments. Furthermore, global circumferential and radial
strains (GCS and GRS, respectively) were obtained by averaging all
segmental peak systolic strain values. Circumferential and radial
peak systolic strain rates were deﬁned as the maximum shortening
and thickening velocity between onset QRS and time of peak systolic
strain, respectively, averaged over all segments.
RNA and RT-PCR
Cardiac tissue was lysed with stainless steel beads (QIAGEN, Venlo,
the Netherlands) in lysis buffer with the TissueLyser LT (QIAGEN,
Venlo, the Netherlands). RNA was isolated from the lysate with mir-
VANA kit (Thermo Fisher Scientiﬁc, Waltham, MA), according to
the manufacturer’s instructions. DNase treatment was performed
with DNAfree kit (Thermo Fisher Scientiﬁc, Waltham, MA), accord-
ing to the manufacturer’s guidelines. Reverse transcription was per-
formed with miScript kit (QIAGEN, Venlo, the Netherlands), using
equal RNA input according to the manufacturer’s instructions.
RT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad,
Hercules, CA) and iCycler iQ (Bio-Rad, Hercules, CA), according to
themanufacturer’s instructions, with 10 ng cDNA as input. The primer
sequences were as follows: mir-103, forward 50-agcagcattgtacagggc-
tatga-30, reverse 50-gaatcgagcaccagttacg-30; Pdk4, forward 50-gcatttct
actcggatgctcatg-30, reverse 50-ccaatgtggcttgggtttcc-30; Ldha, forward
50-ggaaggaggttcacaagcag-30, reverse 50-acccgcctaaggttcat-30; Ndufb3,
forward 50-acagacagtggaaaattgaaggg-30, reverse 50-gcccatgtatctccaa
gcct-30; Cyc1, forward 50-gcattcggaggggtttccag-30, reverse 50-ccgcatgaa-
catctcccca-30; Sdhb, forward 50-aatttgccatttaccgatggga-30, reverse 50-agc
atccaacaccataggtcc-30; and Ucp3, forward 50-ggatttgtgccctcctttctg-30,
reverse 50-cattaaggccctcttcagttgct-30. miR-103/107 qPCR data are
shown as miR-103 alone since the primer set cannot distinguish
between the two miRNA paralogs.
Western Blotting
Protein lysates were prepared from snap-frozen tissues in 500 mL
radio-immunoprecipitation assay (RIPA) SDS (50 mM Tris-HCl,
150 mM sodium chloride, 0.1% SDS, 0.5% sodium deoxycholate, 1%434 Molecular Therapy: Nucleic Acids Vol. 14 March 2019NP-40, proteinase inhibitor cocktail (Roche), and 0.5 mM sodium
orthovanadate) in the TissueLyser LT (QIAGEN, Venlo, the
Netherlands). Cell lysates from nRCMs were prepared in 2 sample
buffer (62.5 mM Tris-HCl, 50 mM dithiothreitol, 10% glycerol,
2% SDS, and 0.01% bromophenol blue). Total protein content of
cell and tissue lysates was determined using the micro bicinchoninic
acid (microBCA) protein assay kit (Thermo Fisher Scientiﬁc,
Waltham, MA). 20 mg protein from tissue or cell lysate was resolved
on SDS-PAGE polyacrylamide gel. The PageRuler protein ladder
(Thermo Fisher Scientiﬁc, Waltham, MA) was used as a molecular
weight reference. Electrophoresis was performed in a Mini-
PROTEAN setup (Bio-Rad, Hercules, CA) for 1.5 h at 110 V. Pro-
teins were transferred to a 0.45-mM polyvinylidene ﬂuoride
(PVDF) membrane (Merck Millipore, Billerica, MA) at 110 V/200
mA for 1 h. The membrane was blocked in 5% milk or BSA in
Tris-buffered saline with 0.1% Tween for 1 h at room temperature,
and it was incubated with primary antibody overnight at 4C with
gentle shaking.
The antibodies against Phospho-Troponin I (Ser23/24, 4004, Cell
Signaling Technology, Danvers, MA, USA), total Troponin I
(4002, Cell Signaling Technology, Danvers, MA, USA), phospho-
phospholamban (Ser16/Thr17, 8496), and total phospholamban
were purchased from Cell Signaling Technology (14562, Danvers,
MA, USA); the antibody against GAPDHwas purchased fromMilli-
pore (CB1001, Burlington, VT, USA); and the antibody against
Phospho-CAMK II (Thr 177) was purchased from Santa Cruz
Biotechnology (28438, Heidelberg, Germany). Horseradish peroxi-
dase (HRP)-linked secondary antibodies anti-mouse immunoglob-
ulin G (IgG), HRP-linked (7076, Cell Signaling Technology,
Danvers, MA, USA) and anti-rabbit IgG, HRP-linked (7074, Cell
Signaling Technology, Danvers, MA, USA) were applied in TBS-T
for 1 h at room temperature. Immunoreactivity was visualized by
a homemade enhanced chemiluminescence reagent (enhancer:
11 mg P-coumaric Acid and 10 mL DMSO; substrate: 10 mL 1 M
Tris-HCl [pH 8.6], 25 mg sodium luminol, 21 mL 30% H202, and
90 mL distilled water), and immunoblot intensities were analyzed
by densitometry with the software Image Studio Lite (Westburg,
Leusden, the Netherlands).
Histology
Parafﬁn-embedded 4-mm left ventricular sections were stained with
H&E and picrosirius red, as described before,33 or GS lectin
Biotinylated Griffonia Simplicifolia Lectin I (Burlingame, CA).
Morphometric analyses were performed using a microscope (Leica
DM2000; Leica, Wetzlar, Germany), camera (Leica DFC295
3Mpix CMOS color), and LAS Image Analysis software (Leica).
Quantiﬁcations of ﬁbrosis via via picrosirius red staining and of
cardiomyocyte area via laminin staining were performed as previ-
ously described.8 Capillary density was analyzed in 8 lectin-stained
sections/mouse at 40magniﬁcation. Sections were analyzed with a
capillary density assessment macro in ImageJ, from which tissue
area (mm2), number of vessels, and number of vessels/mm2 were
calculated.
www.moleculartherapy.orgTransmission Electron Microscopy
Cardiac tissue was ﬁxed with 3% glutaraldehyde in phosphate buffer
and stored at 4C. Tissue was washed with phosphate buffer and ﬁxed
with 1% osmium tetroxide in phosphate buffer containing 0.8%
potassium ferricyanide at 4C. Samples were dehydrated in acetone,
inﬁltrated with Epon resin for 48 h, embedded, and polymerized at
60C for 48 h. Ultrathin sections were obtained using a Leica Ultracut
UC6 ultramicrotome (Leica Microsystems, Vienna, Austria) and
mounted on Formvar-coated copper grids. Staining was performed
with 2% uranyl acetate in water and lead citrate. The sections were
observed in a Tecnai G2 Spirit transmission electron microscope
equipped with a CCD Eagle 4kx4k camera (FEI, Eindhoven, the
Netherlands). Five tissue samples per experimental group were
selected and three pictures per sample were analyzed. Mitochondrial
volume density was calculated as the mitochondria-containing
fraction of a 32-by-32 grid placed on pictures of 1,900 magniﬁca-
tion. To estimate the number and size distribution of all mitochondria
within the cardiac tissue, mitochondria were counted, and the longest
mitochondrial diameter was measured with ImageJ ROI-Manager on
three pictures per sample at 1,900 magniﬁcation. The number of
mitochondria in each size range was calculated as percentage of total
mitochondria number for identical amounts of area in each sample.
Mitochondrial ultrastructure was assessed at 6,800 magniﬁcation.
Five tissue samples per experimental group were selected and three
pictures per sample were analyzed.
In Vitro Experiments
HL-1 cells were cultured according to Dr. Claycomb (Louisiana State
University, NewOrleans, LA).34 nRCMs were isolated and cultured in
6-well and 8-well microscopy m-slides (80826, ibidi, Martinsried,
Germany), as previously described.35 HL-1 cells or nRCMs were
transfected with 30 nM miR-103/107 inhibitors (miRCURY LNA
miRNA inhibitor, Exiqon; sequence 50-CCCTGTACAATGCTGC-30)
or respective controls in combination with transfection reagent
Lipofectamine 2000 (Thermo Fisher Scientiﬁc, Waltham, MA), ac-
cording to the manufacturer’s instructions.
HL-1 Substrate Uptake Experiments
Substrate uptake experiments were performed as previously
described.36 Brieﬂy, palmitate (coupled to BSA in a palmitate:BSA
ratio of 1:3) and deoxy-D-glucose were added to ﬁnal concentrations
of 20 and 4 mM, respectively, with tracer amounts of [14C] palmitate
and 2-deoxy-D-[3H]glucose. After 10 min, uptake was terminated
and unbound substrate was removed by washing the cells with
ice-cold depletion medium containing 0.2 mM phloretin. Cells were
lysed by the addition of 1 M NaOH. Subsequently, incorporated
glucose and palmitate were measured by scintillation counting of
[14C] and [3H].
Liquid Chromatography-MS
Tissue disruption and lysis were performed by use of Tissue Lyser II
(QIAGEN) in a buffer containing 5 M Urea (GE Healthcare) in
50 mM Ammonium bicarbonate (ABC) (Sigma-Aldrich). The lysate
was then reduced with 20 mM DTT for 45 min and alkylated with40 mM iodoacetamide (IAM) for 45 min in the dark. The alkylation
was terminated by 20 mM DDT to consume any excess IAM.
Digestion was performed with a mixture of LysC and Trypsin (Prom-
ega), which was added at a ratio of 1:25 (enzyme to protein). After 2 h
of digestion at 37C in a water bath, the lysate was diluted with 50mM
ABC to 1 M Urea and further digested at 37C overnight. The diges-
tion was terminated by the addition of formic acid (FA) to a total of
1%. Biognosys (Biognosys, Schlieren, Switzerland) indexted Reten-
tion Time standards (iRTs) were added to each peptide sample
according to the manufacturer’s instructions (required for the data-
independent acquisition [DIA] analysis using Spectronaut). Peptide
separation was performed on a Thermo Scientiﬁc (Dionex) Ultimate
3000 Rapid Separation UHPLC system equipped with an Acclaim
PepMap C18 analytical column (2 mM, 100Å, 75 mM  150 mm).
Peptide samples were ﬁrst desalted on an online installed C18 trap-
ping column. After desalting, peptides were separated on the
analytical column with a 90-min linear gradient from 5% to 35%
Acetonitrile (Biosolve) with 0.1% FA at 300 nL/min ﬂow rate. The
UHPLC system was coupled to a Q Exactive HF mass spectrometer
(Thermo Scientiﬁc).
Data-dependent acquisition (DDA) settings were as follows: full MS
scan between 375 and 1,500 m/z at a resolution of 120,000 followed
by tandem MS (MS/MS) scans of the top 15 most intense ions at a
resolution of 30,000. The HRM DIA method consisted of a survey
full MS scan at 120,000 resolution at 350–1,650 m/z. Then 58 DIA
windows were acquired at 30,000 resolution. For protein identiﬁca-
tion, the DDA spectra were analyzed with Proteome Discoverer
(PD) version 2.1.1.21. Within the PD software, the search engine
Sequest was used with the SwissProt mouse database (Mus musculus;
SwissProt TaxID = 10090; version (v.)2017-01-18) and the Biognosys
iRT peptide sequences. The database search was performed with
the following settings: enzyme was trypsin, a maximum of 2 missed
cleavages, minimum peptide length of 6, precursor mass tolerance
of 10 ppm, fragment mass tolerance of 0.02 Da, dynamic modiﬁca-
tions of methionine oxidation and protein N terminus acetylation,
and static modiﬁcation of cysteine carbamidomethylation. The
DDAmeasurements were used to create a spectral library using spec-
tral library generation in Spectronaut 9 (Biognosys, Schlieren,
Switzerland). Only identiﬁcations with false discovery rates (FDR)
of maximum 1% at peptide and protein levels were taken into account
for spectral library generation. For protein quantitation, the DIA
data were analyzed with Spectronaut 9, with the manufacturer’s
recommended default settings. The DDA data were analyzed with
Proteome Discoverer 2.2 (Thermo Scientiﬁc).
Metabolic Flux Analysis
Mitochondrial stress test and glycolytic stress test were performed
on 4-day cultured primary nRCMs by real-time extracellular ﬂux
analyses using a Seahorse XF96 ﬂux analyzer (Seahorse Bioscience,
North Billerica, MA). OCR and ECAR were measured as previously
described.37 For the mitochondrial stress OCR, an indicator of mito-
chondrial respiration was measured.37 Cells were seeded at a density
of 50,000 cells/well in an XF96 cell culture microplate (Agilent). OnMolecular Therapy: Nucleic Acids Vol. 14 March 2019 435
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drial assay medium and placed in a 37C incubator without CO2
for 1 h. An automated Seahorse XF96 protocol consisted of 20-min
calibration and equilibration, followed by synchronized injection of
drugs and/or reagents at optimized concentrations in each of 3 ports
(mixing 4 min followed by a measurement of 4 min). Injection ports
were loaded with the following: Oligomycin (ATP synthase inhibitor)
at 1 mM, FCCP (oxidative phosphorylation uncoupler) at 0.5 mM, and
a mixture of 1 mM Rotenone (respiratory complex I inhibitor) and
1 mM Antimycin A (respiratory complex III inhibitor), as described
previously.37 OCR was recorded and averaged three times for each
conditional cycle. For the glycolysis stress test, ECAR, a surrogate
for anaerobic glycolysis, was measured using the Seahorse XF96
ﬂux analyzer. Cells were seeded at a density of 70,000 cells/well in a
XF96 cell culture microplate (Agilent). On the day of the measure-
ment, cells were washed with XF Glycolytic assay medium and placed
in a 37C incubator without CO2 for 1 h prior to the assay. Injection
ports were loaded with the following: glucose (10 mM), Oligomycin
(2 mM) to stimulate anaerobic glycolysis for ATP production, and
2-deoxyglucose (2-DG) (100 mM) to inhibit glycolysis as described
previously.37 After assay completion, total protein content of cell ly-
sates was determined using the microBCA protein assay kit (Thermo
Fisher Scientiﬁc, Waltham, MA).
Mitochondrial Live-Cell Imaging
Live imaging of mitochondria was performed on primary nRCMs
cultured and transfected in gelatin-coated 8-well microscopy
m-slides (80826, ibidi, Martinsried, Germany). Prior to imaging,
cells were incubated with 250 nM TMRM (T668, Thermo Fisher
Scientiﬁc, Waltham, MA), 3 mg/mL Calcein AM (C1430, Thermo
Fisher Scientiﬁc, Waltham, MA), and 2.5 mg/mL Hoechst
(H21486, Thermo Fisher Scientiﬁc, Waltham, MA) in phenol red
free medium for 30 min at 37C and 5% CO2 to stain mitochon-
dria, cytoplasm, and nuclei, respectively. TMRM is utilized to
monitor mitochondrial membrane potential and mitochondrial
network structure. In healthy mitochondria, ETC and ATP synthe-
sis are efﬁciently coupled, however, defects in the OXPHOS system
affect mitochondrial membrane potential. If membrane potential
is compromised, the retention of TMRM within mitochondria is
hindered and the detectable ﬂuorescent signal decreases. Cells
were washed 3 times with PBS and incubated in phenol red free
medium.
Mitochondria were observed with a CorrSight ﬂuorescence micro-
scope using a Zeiss 63 numerical aperture (NA) 1.4 objective, an
Andromeda spinning-disc module, and a Hamamatsu ORCA-
Flash4.0 V2 camera, resulting in a pixel size of 103 nm (FEI, Eind-
hoven, the Netherlands), in a chamber at 37C and 5% CO2. For
each experimental condition, 10 ﬁelds of view were imaged. Excita-
tion lasers, with wavelengths of 405, 488, and 561 nm, and emission
ﬁlters, with wavelengths of 446, 523, and 600 nm, were used for
visualizing the nuclei, cytosol, and mitochondria, respectively. The
z stacks that contained 100 images each were placed at Nyquist
Z-distance (170 nm) to image whole cardiomyocytes. The z stacks436 Molecular Therapy: Nucleic Acids Vol. 14 March 2019underwent deconvolution using the Constrained Inference for
Linear Mixed Effects Models (CLME) algorithm of Huygens Profes-
sional (SVI Hilversum). Cells were segmented manually on top of
maximum-intensity projections of the channel-merged z stacks for
the analysis of 3–6 cells/ﬁeld of view. Image quantiﬁcation was per-
formed as described before,38 with the exception that our analysis
was performed in 3 dimensions and was written in MATLAB 2017
(MathWorks) complemented with the DipImage toolbox (TU Delft).
In short, all channels were ﬁrst ﬁltered both with a top-hat and a 3D
median ﬁlter, masked using thresholding at a constant value, and
segmented automatically. The volume of the cytoplasm was calcu-
lated by extracting the hole-ﬁlled nuclear volume (as deﬁned by the
Hoechst staining) from the hole-ﬁlled cytosolic volume, which re-
ﬂects the cell volume (as deﬁned by the Calcein staining).
Statistical Analyses
Data are presented as mean ± SEM unless speciﬁed otherwise. Com-
parisons between 2 groups were performed with the 2-tailed Student’s
t tests. For comparisons of more than 2 groups, 1-way ANOVA was
used, followed by post hoc testing with Bonferroni correction for
more groups. For comparisons between the same groups over time,
repeated-measures ANOVA was used, followed by post hoc testing
with Bonferroni correction. Values of p < 0.05 were considered statis-
tically signiﬁcant.
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